ORIC Pharmaceuticals names new chief financial officer
11 September 2019 -

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced yesterday that it has named Dominic Piscitelli as its new chief financial officer.

Piscitelli will serve on the executive leadership team and lead the company's finance, investor relations, and corporate operations functions. He has 20 years of experience including debt and equity financings, in-licensing transactions, acquisitions, marketing partnerships and commercial product launches including XTANDI and Tarceva. Prior to joining ORIC, Piscitelli was CFO of AnaptysBio. Prior to AnaptysBio, he was vice president of Finance, Strategy and Investor Relations at Medivation and played a key role in its acquisition by Pfizer. Earlier, he served in roles of increasing responsibility at Astellas Pharma and OSI Pharmaceuticals, and played a significant role in OSI's acquisition by Astellas. He started his career with KPMG and is a certified public accountant.

Jacob Chacko, ORIC MD, chief executive officer, said, 'We are thrilled to continue attracting top talent to our experienced leadership team, which we've been assembling over the past year. Dominic has a multi-decade record of leadership spanning a range of financial and strategic positions in leading biotechnology companies like AnaptysBio and Medivation. His experience in both private and public company settings have given Dominic broad expertise in capital raising, strategic transactions, and commercial launches, all of which will be critical to ORIC's future as we advance and expand our pipeline of agents targeting oncology resistance and prepare for our next stage of growth.'